PI3K抑制剂在癌症治疗中的作用及未来发展方向

药物化学 Pub Date : 2023-01-01 DOI:10.12677/hjmce.2023.112013

思远郝

{"title":"PI3K抑制剂在癌症治疗中的作用及未来发展方向","authors":"思远郝","doi":"10.12677/hjmce.2023.112013","DOIUrl":null,"url":null,"abstract":"The phosphoinositol 3 kinase (PI3K)-protein kinase B (PKB/AKT) mammalian rapamycin target protein (mTOR) axis is a key signal transduction system that connects oncogenes and multiple receptor categories, participating in many important cellular functions. The abnormal PI3K signaling pathway is one of the most common mutation pathways in cancer. Due to the fact that carcino-*","PeriodicalId":64647,"journal":{"name":"药物化学","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role and Future Directions of PI3K Inhibitors in Cancer Treatment\",\"authors\":\"思远郝\",\"doi\":\"10.12677/hjmce.2023.112013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The phosphoinositol 3 kinase (PI3K)-protein kinase B (PKB/AKT) mammalian rapamycin target protein (mTOR) axis is a key signal transduction system that connects oncogenes and multiple receptor categories, participating in many important cellular functions. The abnormal PI3K signaling pathway is one of the most common mutation pathways in cancer. Due to the fact that carcino-*\",\"PeriodicalId\":64647,\"journal\":{\"name\":\"药物化学\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药物化学\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12677/hjmce.2023.112013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物化学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12677/hjmce.2023.112013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Role and Future Directions of PI3K Inhibitors in Cancer Treatment

The phosphoinositol 3 kinase (PI3K)-protein kinase B (PKB/AKT) mammalian rapamycin target protein (mTOR) axis is a key signal transduction system that connects oncogenes and multiple receptor categories, participating in many important cellular functions. The abnormal PI3K signaling pathway is one of the most common mutation pathways in cancer. Due to the fact that carcino-*

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

药物化学

自引率

0.00%

发文量